Intralymphatic immunotherapy with the diabetes vaccine Diamyd® explained


Diamyd® is a novel antigen-specific immunotherapy for the treatment of autoimmune diabetes. Diamyd® is based on the protein GAD65, an activator of the immune system involved in the pathology of autoimmune diabetes. By preventing the autoimmune destruction of insulin producing cells, Diamyd® has the potential to significantly reduce the complications of type 1 diabetes and LADA. Diamyd® is in Phase IIb clinical development.

Bädda in

Dela det här videoklippet

Om oss

Diamyd Medical är ett svenskt diabetesbolag dedikerat till att bota autoimmun diabetes genom läkemedelsutveckling och investeringar inom stamcellsteknologi och medicinteknik.

Prenumerera